Apertura Gene Therapy

Congratulations to Ben Deverman and his team at the #BroadInstitute! TfR1 Capsid – Science Paper https://lnkd.in/eVKQK_6N The Broad PR on TfR1 Capsid in Science-https://lnkd.in/e5JPpfJz

We are proud to share that Apertura’s Jorge Santiago-Ortiz, Ph.D., Senior Director of CMC, and Christina Fuentes, Ph.D., Senior Consultant at Darkhorse Consulting, will be co-chairing the scientific symposium titled "How to Develop Gene and Cell Therapies with a DEI Forward Approach" at the upcoming American Society of Gene & Cell Therapy (ASGCT) conference. The ASGCT DE&I committee recommends and implements measures to support the promotion of diversity, equity and inclusion among the Society as well as the larger community of individuals impacted by cell and gene therapies. Jorge is a passionate advocate of diversity, equity, and inclusion every day at Apertura. Please join him by attending this symposium at #ASGCT2024. More information on the scientific symposium: https://lnkd.in/e7a8JYNQ More information on the ASGCT DEI committee: https://lnkd.in/ekFqJyPr

We are proud to share that Apertura’s Jorge Santiago-Ortiz, Ph.D., Senior Director of CMC, and Christina Fuentes, Ph.D., Senior Consultant at Darkhorse Consulting, will be co-chairing the scientific symposium titled "How to Develop Gene and Cell Therapies with a DEI Forward Approach" at the upcoming American Society of Gene & Cell Therapy (ASGCT) conference. The ASGCT DE&I committee recommends and implements measures to support the promotion of diversity, equity and inclusion among the Society as well as the larger community of individuals impacted by cell and gene therapies. Jorge is a passionate advocate of diversity, equity, and inclusion every day at Apertura. Please join him by attending this symposium at #ASGCT2024. More information on the scientific symposium: https://lnkd.in/e7a8JYNQ More information on the ASGCT DEI committee: https://lnkd.in/ekFqJyPr

Talk 1: Second Generation AAV Capsids Reprogrammed to Bind Human Transferrin Receptor are Targeted to the Brain and De-targeted from the Liver in human TFRC Knock-in Mice (#120) -Wednesday May 8, 4:45pm - 5:00pm Talk 2: An AAV Capsid Programmed to Bind a Broadly Expressed Human Receptor Mediates Enhanced Gene Delivery to the CNS and Skeletal Muscle in vivo (#217) -Thursday May 9, 5:00pm - 5:15pm Poster 1: Human CA4-Targeting AAV Capsids Efficiently Transduce the CNS in Humanized Mice (#991) -Thursday May 9, 12:00pm Poster 2: Engineering Human CNS Receptor-Targeted Capsids for Improved Antibody Evasion (#1551) -Friday May 10, 12:00pm Poster 3: Benchmarking natural and synthetic AAV capsids for neutralizing antibody evasion (#1553) -Friday May 10, 12:00pm

Looking forward to sharing all the groundbreaking work from Apertura at ASGCT and seeing all the work from others that all have the same aims, making a difference for patients.

#genetherapy #aperturagenetherapy #ASGCT2024 #BroadInstitute 

Our CEO Joseph La Barge sat down with Stan Gloss for the latest episode of Bio-IT World’s Trends from the Trenches podcast.   Joe highlights his unique path from the legal field to biotech and how Apertura is charting a new path for #genetherapy delivery through novel capsid and payload engineering.   Check out the episode to learn what’s next for Apertura and our engineered capsids: bit.ly/3Vx9hTy

What does 2024 hold for #biopharma?   For the latest installation in the 2024 #ScripAsks series, our CEO Joseph La Barge shared his predictions for continued advances in #genetherapy delivery with the potential to improve the treatment of #neurological diseases.   Check it out: bit.ly/49BZlfA

#ICYMI, we recently published the latest installment of f-stop, authored by CEO Joseph La Barge.   Joe highlights the debut of our TfR1 capsids that have been engineered to cross the blood-brain barrier and reach the central nervous system.   Read f/9 to learn how we are expanding the potential of genetic medicines: bit.ly/3NQRS3K